Loading
A phase 3 trial of Etoposide, Carboplatin and Cisplatin in small-cell lung cancer, run by EpicentRx, Inc., active and no longer recruiting.
A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05566041 by EpicentRx, Inc., with 292 participants enrolled, started 2022-08-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: RRx-001 + eLOOP Device and Cisplatin/carboplatin plus etoposide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares EpicentRx and the tag pipeline.
Shares Etoposide, Cisplatin, Carboplatin and the tag pipeline.
Shares Etoposide, Cisplatin, Carboplatin, Small-cell lung cancer and the tag pipeline.
Shares Etoposide, Cisplatin, Small-cell lung cancer and the tag pipeline.
Shares Etoposide, Small-cell lung cancer and the tag pipeline.
Shares Etoposide, Cisplatin, Carboplatin and the tag pipeline.
Shares Cisplatin, Carboplatin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/